1: Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman 
GJ, Sharpe AH. PD-L1 on tumor cells is sufficient for immune evasion in
immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017 Apr
3;214(4):895-904. doi: 10.1084/jem.20160801. Epub 2017 Mar 16. PubMed PMID:
28302645.


2: Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT,
Daugherty CZ, Koenig L, Yu K, Sica GL, Sharpe AH, Freeman GJ, Blazar BR, Turka
LA, Owonikoko TK, Pillai RN, Ramalingam SS, Araki K, Ahmed R. Rescue of exhausted
CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017 Mar
31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9. PubMed
PMID: 28280249.


3: Sharpe AH. Introduction to checkpoint inhibitors and cancer immunotherapy.
Immunol Rev. 2017 Mar;276(1):5-8. doi: 10.1111/imr.12531. PubMed PMID: 28258698; 
PubMed Central PMCID: PMC5362112.


4: Sage PT, Ron-Harel N, Juneja VR, Sen DR, Maleri S, Sungnak W, Kuchroo VK,
Haining WN, Chevrier N, Haigis M, Sharpe AH. Suppression by T(FR) cells leads to 
durable and selective inhibition of B cell effector function. Nat Immunol. 2016
Dec;17(12):1436-1446. doi: 10.1038/ni.3578. Epub 2016 Oct 3. PubMed PMID:
27695002.


5: McArdel SL, Brown DR, Sobel RA, Sharpe AH. Anti-CD48 Monoclonal Antibody
Attenuates Experimental Autoimmune Encephalomyelitis by Limiting the Number of
Pathogenic CD4+ T Cells. J Immunol. 2016 Oct 15;197(8):3038-3048. Epub 2016 Aug
31. PubMed PMID: 27581174; PubMed Central PMCID: PMC5356934.


6: Rigas D, Lewis G, Aron JL, Wang B, Banie H, Sankaranarayanan I, Galle-Treger
L, Maazi H, Lo R, Freeman GJ, Sharpe AH, Soroosh P, Akbari O. Type 2 innate
lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity
and requires inducible T-cell costimulator-inducible T-cell costimulator ligand
interaction. J Allergy Clin Immunol. 2016 Oct 4. pii: S0091-6749(16)31087-9. doi:
10.1016/j.jaci.2016.08.034. [Epub ahead of print] PubMed PMID: 27717665; PubMed
Central PMCID: PMC5378695.


7: Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, 
Lee J, Nasti TH, Sharpe AH, Freeman GJ, Germain RN, Nakaya HI, Xue HH, Ahmed R.
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.
Nature. 2016 Sep 15;537(7620):417-421. doi: 10.1038/nature19330. Epub 2016 Aug 2.
PubMed PMID: 27501248; PubMed Central PMCID: PMC5297183.


8: Karunarathne DS, Horne-Debets JM, Huang JX, Faleiro R, Leow CY, Amante F,
Watkins TS, Miles JJ, Dwyer PJ, Stacey KJ, Yarski M, Poh CM, Lee JS, Cooper MA,
Rénia L, Richard D, McCarthy JS, Sharpe AH, Wykes MN. Programmed Death-1 Ligand
2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing
CD4(+) T Cell Immunity. Immunity. 2016 Aug 16;45(2):333-45. doi:
10.1016/j.immuni.2016.07.017. PubMed PMID: 27533014.